Risk of contralateral breast cancer after tamoxifen use among Danish women

Annals of Epidemiology

Volumn 24, Issue 11, 2014, Pages 843-848

  Mellemkjær, Lene ^a   Steding Jessen, Marianne ^a   Frederiksen, Kirsten ^a   Andersson, Michael ^b   Ejlertsen, Bent ^b,c   Jensen, Maj Britt ^c   Olsen, Jørgen H ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b FINSEN LABORATORY   (Denmark)

^c University of Copenhagen   (Denmark)

Author keywords

Breast neoplasms; Cohort studies; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SIZE; DENMARK; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MENOPAUSE; PARTIAL MASTECTOMY; POSTMENOPAUSE; BREAST NEOPLASMS; INCIDENCE; MIDDLE AGED; RISK; RISK FACTOR; TIME;

ADULT; AGED; BREAST NEOPLASMS; DENMARK; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; POSTMENOPAUSE; RISK; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TIME FACTORS;

EID: 84908304835     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2014.08.003     Document Type: Article

References (21)

1. Davies C., Godwin J., Gray R., Clarke M., Cutter D., Darby S., et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378(9793):771-784.
2. Alkner S., Bendahl P.O., Ferno M., Nordenskjold B., Ryden L. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: results from a controlled randomised trial. Eur J Cancer 2009, 45(14):2496-2502.
3. Bertelsen L., Bernstein L., Olsen J.H., Mellemkjaer L., Haile R.W., Lynch C.F., et al. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. JNatl Cancer Inst 2008, 100(1):32-40.
4. Newcomb P.A., Solomon C., White E. Tamoxifen and risk of large bowel cancer in women with breast cancer. Breast Cancer Res Treat 1999, 53(3):271-277.
5. Schaapveld M., Visser O., Louwman W.J., Willemse P.H., de Vries E.G., van der Graaf W.T., et al. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 2008, 110(1):189-197.
6. Bouchardy C., Benhamou S., Fioretta G., Verkooijen H.M., Chappuis P.O., Neyroud-Caspar I., et al. Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat 2011, 127(1):233-241.
7. Cook L.S., Weiss N.S., Schwartz S.M., White E., McKnight B., Moore D.E., et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. JNatl Cancer Inst 1995, 87(18):1359-1364.
8. Gnant M., Harbeck N., Thomssen C. St. Gallen 2011: summary of the consensus discussion. Breast Care (Basel) 2011, 6(2):136-141.
9. Moller S., Jensen M.B., Ejlertsen B., Bjerre K.D., Larsen M., Hansen H.B., et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 2008, 47(4):506-524.
10. Gjerstorff M.L. The Danish Cancer Registry. Scand J Public Health 2011, 39(7 Suppl):42-45.
11. Bjerregaard B., Larsen O.B. The Danish Pathology Register. Scand J Public Health 2011, 39(7 Suppl):72-74.
12. Vichapat V., Garmo H., Holmqvist M., Liljegren G., Warnberg F., Lambe M., et al. Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based study. JClin Oncol 2012, 30(28):3478-3485.
13. Vichapat V., Gillett C., Fentiman I.S., Tutt A., Holmberg L., Luchtenborg M. Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways. Eur J Cancer 2011, 47(13):1919-1927.
14. Horn P.L., Thompson W.D. Risk of contralateral breast cancer. Associations with histologic, clinical, and therapeutic factors. Cancer 1988, 62(2):412-424.
15. Hackshaw A., Roughton M., Forsyth S., Monson K., Reczko K., Sainsbury R., et al. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. JClin Oncol 2011, 29(13):1657-1663.
16. Nordenskjold B., Rosell J., Rutqvist L.E., Malmstrom P.O., Bergh J., Bengtsson N.O., et al. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. JNatl Cancer Inst 2005, 97:1609-1610.
17. Fisher B., Dignam J., Bryant J., Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. JNatl Cancer Inst 2001, 93(9):684-690.
18. Li C.I., Daling J.R., Porter P.L., Tang M.T., Malone K.E. Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer. Cancer Res 2009, 69(17):6865-6870.
19. Cuzick J., Sestak I., Bonanni B., Costantino J.P., Cummings S., DeCensi A., et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013, 381(9880):1827-1834.
20. Howell A., Evans D.G. Breast cancer prevention: SERMs come of age. Lancet 2013, 381(9880):1795-1797.
21. Cuzick J., Sestak I., Baum M., Buzdar A., Howell A., Dowsett M., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010, 11(12):1135-1141.